“Visit us at CPhI India 2008 at Mumbai ,India -28 November - 30 November 2008,at Hall 6,Stand No:G8”

  Commercial Scale
  Antitubercular
  Pyrazinamide
  Isoniazid
  Rifampicin

  Antimalarial
  Artesunate
  Arteether
  Artemether
  Dihydroartemisinin
  Lumefantrine

  Macrolides
  Azithromycin
  Clarithromycin
  Erythromycin base
  Erythromycin estolate
  Erythromycin ethylsuccinate
  Erythromycin oxime  (intermediate)
  Erythromycin phosphate
  Erythromycin propionate
  Erythromycin stearate

  Antihypertensive
  Lisinopril dihydrate
  Losartan potassium
  Irbesartan
  Valsartan

  Antiepileptic
  Sodium valproate
  Valproic acid
  Divalproex sodium

  Antiosteoporotic
  Alendronate sodium
  Zoledronic acid

  Sedative, Hypnotic
  Zopiclone

  Antidepressant
  Venlafaxine hydrochloride

  Antihistaminic   
  Cetirizine dihydrochloride
  Meclizine dihydrochloride
  Hydroxyzine dihydrochloride

  Antithrombotic
  Clopidogrel bisulphate  

  Pilot Plant Scale
  Carvedilol
  Pioglitazone hydrochloride
  Rosiglitazone maleate
  Eszopiclone
  
  R & D Scale
  Candesartan
  Eprosartan
  Olmesartan
  Telmisartan

  Development
  Benazepril hydrochloride
  Desvenlafaxine
  Levocetirizine
  Ramipril
  Rifabutin
  Rifapentine
  Risedronic acid

     Product under patent  offered  only
      for exempted research, clinical and
      development  purposes. Only  non-
      infringing   products   and  processes
      are offered, subject to patent status
      verification by client.
Calyx at CPhI Worldwide 2008, Frankfurt, Germany

    

Calyx received an overwhelming response during the recent CPhI Worldwide 2008 held in Frankfurt,Germany. The International Sales & Business Development team had many meetings that were organized well in advance. Though the exhibition venue was vast, our valued customers & supply chain partners could make it for the meetings in time. The Calyx team is now busy in interacting with the customers to keep up the commitments agreed upon during the meetings. We sincerely thank all the people who took the time out in meeting with us during September 30 – October 2,2008.
Safety Award from National safety Council

Calyx team receiving the Safety Award from Arvind R. Doshi, Chairman, National Safety Council (Maharashtra Chapter) at the award function held in West End Hotel, Mumbai on 20 September 2008. 

Calyx Chemicals and Pharmaceuticals Limited got a plaque and certificate from National safety council (Maharashtra Chapter) for achieving the ‘Lowest Accident Frequency Rate' in Paper, Sugar and Pharmaceutical industry group. The award function was attended by more than 200 participants from different industries.  There was a seminar session prior to the award function, wherein deliberations were made by distinguished specialists covering - impact of industrialization on environment, Kyoto protocol and global warming.

National Safety Council (NSC) was set up by the Ministry of Labour, Government of India in 1966, as an autonomous body to generate, develop and sustain a voluntary movement on Safety, Health and Environment at the national level. Considering the long felt need of its member-organizations for recognition of their outstanding performance in the field of occupational safety and health, NSC has introduced a Safety Award Scheme since 1998.

Safety comes from man's mastery of its environment & of himself. It is further influenced by individual's efforts and group co-operation. Only informed, alert, and skillful people who respect themselves and have regard for the welfare of others can achieve safety.

At Calyx safety aspects are built in the basic and detailed designing of equipment and facilities, in proper layout and strict adherence to the guiding norms during erection, commissioning and operation. Further we believe that even after all these inbuilt controls, the human aspect plays the most crucial role in ensuring safety since they are more prone to risks.

Here, attention to Safety, Health and Environment is not a matter of choice or priority, it is a matter of absolute conviction and commitment. We resolutely promote Safety, Health & Environment, both on and off the job and have worked over two million man hours without reportable accident.
 
Glimpses of Past Events
  CPhI India 2007

  CPhI Worldwide 2007

  Chemspec Europe 2008

  Quality Excellence Award

  Calyx partners with The Clinton   Foundation

  Calyx Quality Policy

  SHE Policy

Disclaimer:
"The information in this e-mail and any attachments is confidential and may be legally privileged. It is intended solely for the addressee or addressees. If you are not an intended recipient, please delete the  message and any   attachments and notify the sender of  misdelivery. Any use or disclosure of  the  contents of either is unauthorized  and  may   be unlawful. All  liability  for viruses is excluded to the fullest   extent permitted by law. Any views   expressed in this message  are those of the individual sender, except where the sender states them, with requisite authority, to be those of the specific Calyx company."

India Operations: Mr. Jitendra Shah : +91-22-28031520                    jitendra_shah@calyxindia.com
Europe Operations: Mr. Prashant Ogale : +91-251-2438310 ext: 585 prashant_ogale@calyxindia.com
US Operations: Mr. Bharat K. Shah : +1-860-6910186                      bharat.k.shah@calyxusa.com
Japan Operations: Dr. Sanjeev Gupte : +91-251-2438310                 sanjeev_gupte@calyxindia.com
Calyx Chemicals & Pharmaceuticals Ltd.
Regd. Office: Unit No.2 Marwah's Complex, Marwaha Estate, SakiVihar Road, Andheri (E),
Mumbai - 400072, India Tel: +91-22-28031500, Fax: +91-22-66466817
Corp Office: A 37-38 MIDC -Phase -1, Golavli Kalyan Shil Road, Dombivili (E) Dist. Thane 421203,
IndiaTel : +91-251-2438310 Fax: +91-2512438726

New Jersey: Tel: +1-732-579-8569, Fax: +1-732-321-6562
Los Angeles: +1-213-219-7773, Fax: +1-775-514-1230,
Connecticut: Tel: +1-860-910-4279, Fax: +1-860-908-3177
Email: pharmanews@calyxindia.com        URL: www.calyxindia.com
To unsubscribe from this Newsletter send blank email to pharmanews@calyxindia.com
2008/22-CPN